Biomarin Pharmaceutical (BMRN) Gross Margin (2009 - 2026)
Biomarin Pharmaceutical (BMRN) recorded quarterly Gross Margin of 74.55% in Q1 2026, up 8.87% on a QoQ basis from 68.47% in Q4 2025, and down 511.0% year-over-year from 18.14% in Q1 2025.
Biomarin Pharmaceutical (BMRN) Gross Margin (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical has disclosed Gross Margin across 18 years of filings, most recently posting 74.55% for Q1 2026.
- Quarterly Gross Margin fell 511.0% year-over-year to 74.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 76.53% (down 291.0% YoY) and the FY2025 annual result came in at 77.73%, down 194.0% from the prior year.
- Gross Margin climbed to 74.55% in Q1 2026, from 68.47% in the prior quarter.
- Over five years, Gross Margin peaked at 81.95% in Q3 2025 and troughed at 68.47% in Q4 2025.
- A 5-year average of 77.73% and a median of 77.97% in 2023 frame the typical range for Gross Margin.
- Biggest YoY gain for Gross Margin was 722 bps in 2025; the steepest drop was 1331 bps in 2025.
- Tracing BMRN's Gross Margin over 5 years: stood at 72.72% in 2022, then advanced by 8 bps to 78.66% in 2023, then gained by 4 bps to 81.78% in 2024, then decreased by 16 bps to 68.47% in 2025, then rose by 9 bps to 74.55% in 2026.
- Business Quant data shows BMRN's Gross Margin at 74.55% in Q1 2026, 68.47% in Q4 2025, and 81.95% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Biomarin Pharmaceutical | 10.52 Bn | 8.29 Bn | 571.21 Mn | 74.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.55% |
| Dec 31, 2025 | 68.47% |
| Sep 30, 2025 | 81.95% |
| Jun 30, 2025 | 81.82% |
| Mar 31, 2025 | 79.66% |
| Dec 31, 2024 | 81.78% |
| Sep 30, 2024 | 74.73% |
| Jun 30, 2024 | 81.68% |
| Mar 31, 2024 | 80.71% |
| Dec 31, 2023 | 78.66% |
| Sep 30, 2023 | 77.97% |
| Jun 30, 2023 | 78.06% |
| Mar 31, 2023 | 77.29% |
| Dec 31, 2022 | 72.72% |
| Sep 30, 2022 | 76.99% |
| Jun 30, 2022 | 76.93% |
| Mar 31, 2022 | 77.48% |
| Dec 31, 2021 | 73.38% |
| Sep 30, 2021 | 74.67% |
| Jun 30, 2021 | 74.67% |